{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:22:54Z","timestamp":1781029374167,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chidamide has demonstrated significant clinical benefits for patients with relapsed\/refractory (R\/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R\/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1\u20132. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R\/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2021.750323","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T07:54:17Z","timestamp":1636012457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Weiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of Lymphoma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3037","article-title":"Improving Survival of 3760 Patients With Lymphoma: Experience of an Academic Center Over Two Decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3744-z","article-title":"A Retrospective Study of the CHOP, CHOPE, and CHOPE\/G Regimens as the First-Line Treatment of Peripheral T-Cell Lymphomas","volume":"83","author":"Liu","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Report of 340 Cases From the International Peripheral T-Cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-021-00200-x","article-title":"Correlation of Mutational Landscape and Survival Outcome of Peripheral T-Cell Lymphomas","volume":"10","author":"Ye","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873","article-title":"Recurrent Mutations in Epigenetic Regulators, RHOA and FYN Kinase in Peripheral T Cell Lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and is a Recurrent Event During Human Lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509","article-title":"A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 Mutations are Frequent in Angioimmunoblastic T-Cell Lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1568011043352948","article-title":"Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors","volume":"4","author":"Xie","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): A New Histone Deacetylase Inhibitor of the Benzamide Class With Antitumor Activity and the Ability to Enhance Immune Cell-Mediated Tumor Cell Cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a Novel Histone Deacetylase Inhibitor, Induces G1 Arrest, ROS-Dependent Apoptosis and Differentiation in Human Leukaemia Cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70522","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment With Decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1039\/C4MD00350K","article-title":"Discovery of an Orally Active Subtype-Selective HDAC Inhibitor, Chidamide, as an Epigenetic Modulator for Cancer Treatment","volume":"5","author":"Pan","year":"2014","journal-title":"Med Chem Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.03.011","article-title":"Non-Toxic Dose Chidamide Synergistically Enhances Platinum-Induced DNA Damage Responses and Apoptosis in Non-Small-Cell Lung Cancer Cells","volume":"68","author":"Zhou","year":"2014","journal-title":"BioMed Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I Study of Chidamide (CS055\/HBI-8000), a New Histone Deacetylase Inhibitor, in Patients With Advanced Solid Tumors and Lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the Treatment of Relapsed\/Refractory Peripheral T-Cell Lymphoma: Pivotal Study Update Demonstrates Durable Responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2691","article-title":"Romidepsin Treatment for Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma: Real-Life Data From a National Multicenter Observational Study","volume":"37","author":"Shimony","year":"2019","journal-title":"Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.750323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T15:04:14Z","timestamp":1636124654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.750323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":27,"alternative-id":["10.3389\/fonc.2021.750323"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.750323","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"article-number":"750323"}}